Method and product for treating cancer in pets

• US 7,129,230 B2
• Filed: 03/12/2001
• Issued: 10/31/2006
• Est. Priority Date: 03/12/2001
• Status: Expired due to Fees

• Current Assignee: NPPC Services Incorporated
• Original Assignee: Nestec SA (Nestle SA)
• Inventors: Inpanbutr, Nongnuch
• Primary Examiner(s): HUI, SAN MING R
• Application Number:
  US09/804,111
• Publication Number:
  US 20020127267A1
• Time in Patent Office: 2,059 Days
• Field of Search: 514/167, 424/439
• US Class Current: 514/167
• CPC Class Codes: A23K 20/174 Vitamins
• CPC Class Codes: A23K 40/30 by encapsulating; by coating
• CPC Class Codes: A23K 50/40 for carnivorous animals, e.g. cats or dogs
• CPC Class Codes: A23K 50/48 Moist feed
• CPC Class Codes: A61K 31/59 Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems

Abstract

A pet food containing vitamin D analogs for use in treatment of cancer in pets, such as dogs and cats, is described. Also described is a method for treating pets, such as dogs and cats, for cancer by feeding the pet a pet food containing at least one vitamin D analog.

Claims

1. A method of treating SCC 2/88, a canine squamous carcinoma cell line, for cancer, comprising the step of feeding a dog a dog food comprising a proteinaceous component, a farinaceous component, and a therapeutic agent comprising a vitamin D analog selected from the group consisting of 1α

,25-(OH)₂D₃, 1α

,25-(OH)₂-16-ene-23-yne-D₃ and 1α

,25-(OH)₂-22,24-diene-24,26,27-trihomo-D₃ and stereoisomers thereof.

2. The method of claim 1, wherein the vitamin D analog is 1α

,25-(OH)₂D₃ and stereoisomers thereof.

3. The method of claim 1, wherein the vitamin D analog is 1α

,25-(OH)₂-16-ene-23-yne-D₃ and stereoisomers thereof.

4. The method of claim 1, wherein the vitamin D analog is 1α

,25-(OH)₂-22,24-diene-24,26,27-trihomo-D₃ and stereoisomers thereof.

5. The method of claim 1, wherein the vitamin D analog is administered in combination with a bone agent, a cytotoxic agent, an immuno response regulating agent, an antinflammatory agent or combinations thereof.

6. The method of claim 1, wherein the dog is fed from about 0.025 to about 500 nmol/kg of body weight of the patient per day of the vitamin D analog.

7. The method of claim 1, wherein the dog is fed from about 0.025 to about 100 nmol/kg of body weight of the patient per day of the vitamin D analog.

8. The method of claim 1, wherein the dog is fed from about 0.025 to about 10 nmol/kg of body weight of the patient per day of the vitamin D analog.

9. The method of claim 1, wherein the dog is fed from about 0.025 to about 1.0 nmol/kg of body weight of the patient per day of the vitamin D analog.

10. The method of claim 1, wherein the dog is fed a therapeutically efficacious dosage of a vitamin D analog.

11. The method of claim 1 wherein the Vitamin D analog is administered in combination with a bone agent comprising at least one of conjugated estrogens, conjugated estrogen equivalents, anti-estrogens, calcitonin, bisphosphonates, calcium supplements, calcium receptor agonists, cobalamin, pertussis toxin, boron, dehydroepiandrosterone, activin and bone morphogenic protein.

12. The method of claim 1 wherein the Vitamin D analog is administered in combination with a cytotoxic agent comprising at least one of estramustine phosphate, prednimustine, cisplatin, 5-fluoro-uracil, melphalan, hydroxyurea, mitomycin, idarubicin, methotrexate, adriamycin, daunomycin, cyclophosphamide, doxorubicin, vincristine and pregnisone.

13. The method of claim 1 wherein the Vitamin D analog is administered in combination with an anti-inflammatory agent comprising at least one of a steroidal anti-inflammatory agent and a non-steroidal anti-inflammatory agent.

14. The method of claim 13 wherein the steroidal anti-inflammatory agent includes corticosteroids.

15. The method of claim 13 wherein the non-steroidal anti-inflammatory agent includes at least one of salicylates and naproxen.

16. The method of claim 1 wherein feeding the dog a therapeutic agent comprising a vitamin D analog comprises producing a pharmaceutical agent from admixture which includes at least one of a pharmaceutically acceptable organic carrier substance and a pharmaceutically acceptable inorganic carrier substance.

17. The method of claim 16 wherein the pharmaceutically acceptable organic carrier substance and the pharmaceutically acceptable inorganic carrier substance include at least one of water, salt and buffer solutions, alcohols, gum arabic, mineral and vegetable oils, benzyl alcohols, polyethylene glycols, gelatine, carbohydrates such as lactose, amylose or starch, magnesium stearate, talc, silicic acid, viscous paraffin, perfume oil, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, hydroxy methylcellulose, and polyvinyl pyrrolidone.

18. The method of claim 16 further comprising mixing the pharmaceutical agent with an auxiliary agent, the auxiliary agent including one or more of lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, flavoring and/or aromatic active compounds.

19. A method of providing a therapeutic agent to a pet, wherein the agent comprises a vitamin D analog selected from the group consisting of 1α

,25-(OH)₂D₃, 1α

,25-(OH)₂-16-ene-23-yne-D₃, and 1α

,25-(OH)₂-22,24-diene-24,26,27-trihomo-D₃ and stereoisomers thereof, said method comprising providing a pet food including a proteinaceous component, a farinaceous component, and the agent, and feeding the pet food to a pet.

20. The method of claim 19 wherein the vitamin D analog is administered in combination with at least one of a bone agent, a cytotoxic agent, an immuno response regulating agent, and an anti-inflammatory agent.

21. The method of claim 19 wherein the dog is fed from about 0.025 to about 500 nmol/kg of body weight of the dog per day of the vitamin D analog.

22. The method of claim 19 wherein the dog is fed from about 0.025 to about 100 nmol/kg of body weight of the dog per day of the vitamin D analog.

23. The method of claim 19 wherein the dog is fed from about 0.025 to about 10 nmol/kg of body weight of the dog per day of the vitamin D analog.

24. The method of claim 19 wherein the dog is fed from about 0.025 to about 1.0 nmol/kg of body weight of the dog per day of the vitamin D analog.

25. The method of claim 19 wherein the dog is fed a therapeutically efficacious dosage of the vitamin D analog.

26. A method of administering a pharmaceutical agent to a pet, wherein the agent comprises a vitamin D analog selected from the group consisting of 1α

,25-(OH)₂D₃, 1α

,25-(OH)₂-16-ene-23-yne-D₃, and 1α

,25-(OH)₂-22,24-diene-24,26,27-trihomo-D₃ and stereoisomers thereof, said method comprising providing a pet food including a proteinaceous component, a farinaceous component, and the agent, and feeding the pet food to a pet.

27. The method of claim 26 wherein feeding the pet food to a pet comprises producing a pharmaceutical agent from an admixture which includes at least one of a pharmaceutically acceptable organic carrier substance and a pharmaceutically acceptable inorganic carrier substance.

28. The method of claim 27 wherein the pharmaceutically acceptable organic carrier substance and the pharmaceutically acceptable inorganic carrier substance include at least one of water, salt (buffer) solutions, alcohols, gum arabic, mineral and vegetable oils, benzyl alcohols, polyethylene glycols, gelatine, carbohydrates such as lactose, amylose or starch, magnesium stearate, talc, silicic acid, viscous paraffin, perfume oil, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, hydroxy methylcellulose, and polyvinyl pyrrolidone.

29. The method of claim 27 further comprising mixing the pharmaceutical agent with an auxiliary agent that includes one or more of lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, flavoring and/or aromatic active compounds.

30. The method of claim 26 wherein the dog is fed from about 0.025 to about 500 nmol/kg of body weight of the dog per day of the vitamin D analog.

31. The method of claim 26 wherein the dog is fed a therapeutically efficacious dosage of a vitamin D analog.